I'll go for $1.60.
The stock is well supported by insto's and further product approvals bode well for the share price.
The company currently has 35 products in its pipeline that target sales of >US7bn and of those, 17 are currently pending approval with the FDA. One such product in the pipeline is Dofetilide which is a generic version of Pfizer's Tikosyn which treats irregular heartbeat and generated US$170million in sales for Pfizer in 2015. MYX' generic version is expected to be approved this calendar year.
Approval would give the share price a bit of a kick along.
Sales momentum in the general products division is strong but competition in this sector has also increased.
Company continues to build scale and perform well but the share price has run hard recently so unless there are product approvals before June 30, it probably won't run much further from here.
A big reason for my confidence in this company is that it has great management
Be interested to hear others' thoughts.
Price Prediction, page-2
-
- There are more pages in this discussion • 25 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Add MYX (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
$4.40 |
Change
0.140(3.29%) |
Mkt cap ! $374.3M | |||
| Open | High | Low | Value | Volume |
| $4.25 | $4.43 | $4.25 | $618.9K | 141.5K |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 10 | 2957 | $4.40 |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| $4.41 | 968 | 1 |
View Market Depth
| Last trade - 16.10pm 12/07/2024 (20 minute delay) ? |
| MYX (ASX) Chart |